Exploring nitric oxide as a crucial prognostic biomarker of coronary artery disease

• Published in: Prostaglandins & other lipid mediators 2023-04, Vol.165, p.106717, Article 106717
• Main Authors: Adam, Lina N., Oraha, Ashur Y., Shekha, Mudhir S., Al-Habib, Omar A.M.
• Format: Article
• Language: English
• Subjects: area under curve (AUC); Biomarkers; Case-Control Studies; Coronary artery disease (CAD); Coronary Artery Disease - genetics; Endothelial nitric oxide synthase (eNOS); Genotype; Humans; Nitric Oxide; Nitric Oxide Synthase Type III - genetics; Prognosis; serum NO
• ISSN: 1098-8823; 2212-196X
• DOI: 10.1016/j.prostaglandins.2023.106717

The study aimed to examine if the polymorphism of the endothelial nitric oxide synthase (eNOS) gene variable number of tandem repeats (VNTR) and the serum NO levels are associated with CAD. Case-control study, 70 CAD and 30 control subjects were enrolled. The eNOS gene polymorphism was measured by polymerase chain reaction–agarose gel electrophoresis and the serum NO was assessed by using an ELISA plate and reader covering 540 nm. Uncovering the area under curve (AUC) for serum NO, which was (0.6821), indicating that NO seemed to be a critical prognostic biomarker of CAD; also, glucose, serum creatinine and total bilirubin proved to be significant predictors of CAD with AUC (0.6793, 0.6717 and 0.6662) respectively. Furthermore, higher serum NO levels were associated with the eNOS (ab) genotype. Revealing the intron (a) allele was protective against CAD. Moreover, diminished levels of serum NO in CAD groups compared to controls (P